Moderna’s Personalized mRNA Cancer Vaccine Clears a Major Phase 3 Hurdle
Moderna and Merck’s personalized mRNA cancer vaccine has delivered positive Phase 3 results in high-risk melanoma, reducing the likelihood of the disease returning when combined with Keytruda.